UPDATES IN MEDICINE

2021-06-21 03:05:48 ​​ Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

● Interpretation - Our study suggests that the ARB telmisartan, a widely used antihypertensive drug, is safe and could reduce morbidity and mortality in hospitalized patients infected with SARS -CoV-2 by anti-inflammatory effects.


Join @Updates_in_Medicine
@The_Lancet Open / Comment

2021-06-20 05:21:32 ​​ COVID Vaccine in Pregnant Women

● mRNA Covid-19 Vaccine Safety in Pregnant Persons - Preliminary data from the CDC “v-safe after vaccination health checker” surveillance system, the v-safe pregnancy registry, and the Vaccine Adverse Event Reporting System did not show any obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines. More data are needed to better inform maternal, pregnancy, and infant outcomes.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-19 05:00:15 ​​ Delta COVID variant becoming globally dominant, WHO official says

The Delta variant of COVID-19, first identified in India, is becoming the globally dominant variant of the disease, the World Health Organization’s chief scientist said on Friday.


Join @COVID19_and_Medical_News Open / Comment

2021-06-18 19:39:16 ​​ Hypothermia or Normothermia after Cardiac Arrest

This trial randomly assigned patients with coma after out-of-hospital cardiac arrest to undergo targeted hypothermia at 33°C or normothermia with treatment of fever. At 6 months, there were no significant between-group differences regarding death or functional outcomes.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-17 19:47:06 ​​ Treatment of COVID associated Multisystem Inflammatory Syndrome in Children

An observational cohort study evaluated immunomodulatory therapy of multisystem inflammatory syndrome in children by comparing IVIG, IVIG plus glucocorticoids, or glucocorticoids alone. The investigators found no evidence of the superiority of any of the three therapies, although significant differences may emerge as more data accrue.


Join @Updates_in_Medicine
@The_NEJM Open / Comment

2021-06-17 04:59:58 ​​ Tofacitinib for Covid-19 Pneumonia

Patients who were hospitalized with Covid-19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group.


Join @Updates_in_Medicine
@The_NEJM Open / Comment